Inhibition of NLRC5 attenuates the malignant growth and enhances the sensitivity of gastric cancer cells to 5‑FU chemotherapy by blocking the carcinogenic effect of YY1

Liang,Shan; Xiang,Tingting; Liu,Shiyu; Xiang,Wei

doi:10.3892/etm.2022.11538

Inhibition of NLRC5 attenuates the malignant growth and enhances the sensitivity of gastric cancer cells to 5‑FU chemotherapy by blocking the carcinogenic effect of YY1

Authors:
- Shan Liang
- Tingting Xiang
- Shiyu Liu
- Wei Xiang
View Affiliations

Affiliations: College of Modern Agriculture and Bioengineering, Yangtze Normal University, Chongqing 408000, P.R. China
Published online on: July 28, 2022 https://doi.org/10.3892/etm.2022.11538
Article Number: 601
Copyright: © Liang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Gastric cancer (GC) is one of the commonest malignant tumors of the digestive system, characterized by high morbidity and mortality rates. It has been reported that NOD like receptor (NLR) family, CARD domain containing 5 (NLRC5) serves an important role in the occurrence and development of GC. Therefore, the current study aimed to investigate the role of NLRC5 in GC. The mRNA and protein expression levels of NLRC5 in GC cell lines were determined by reverse transcription‑quantitative PCR and western blot analysis, respectively. Additionally, following NLRC5 knockdown, cell proliferation, invasion and migration were evaluated using Cell Counting Kit 8, colony formation, wound healing and Transwell assays, and western blot analysis. The NLRC and Yin Yang 1 (YY1) expression in the AGS cells with 5‑FU resistance were detected by western blotting. The sensitivity of GC cells to 5‑fluorouracil (5‑FU) was detected by flow cytometry and western blot analysis. Additionally, the binding capacity of YY1 on NLRC5 promoter was predicted using JASPAR database and it was further verified by chromatin immunoprecipitation and luciferase reporter assays. Finally, to elucidate the mechanism underlying the effect of NLRC5 on GC, YY1 was overexpressed and NLRC5 was silenced in GC cell lines. The results showed that NLRC5 was abnormally upregulated in GC cells. In addition, NLRC5 knockdown significantly attenuated the proliferation, invasion and migration abilities of GC cells, while it enhanced the sensitivity of GC cells to 5‑FU. The above effects were regulated by the YY1 transcription factor. Overall, the results of the present study indicated that NLRC5 silencing could reduce the malignant growth and enhance the sensitivity of GC cells to 5‑FU chemotherapy via inhibiting the carcinogenic effect of YY1.

View Figures

View References

1	Correa P: Gastric cancer: Overview. Gastroenterol Clin North Am. 42:211–217. 2013.PubMed/NCBI View Article : Google Scholar
2	Liu LP, Sheng XP, Shuai TK, Zhao YX, Li B and Li YM: Helicobacter pylori promotes invasion and metastasis of gastric cancer by enhancing heparanase expression. World J Gastroenterol. 27:3138–3141. 2021.PubMed/NCBI View Article : Google Scholar
3	Martinez-Jimenez F, Muinos F, Sentis I, Deu-Pons J, Reyes-Salazar I, Arnedo-Pac C, Mularoni L, Pich O, Bonet J, Kranas H, et al: A compendium of mutational cancer driver genes. Nat Rev Cancer. 20:555–572. 2020.PubMed/NCBI View Article : Google Scholar
4	Tang F, Xu Y and Zhao B: NLRC5: New cancer buster? Mol Biol Rep. 47:2265–2277. 2020.PubMed/NCBI View Article : Google Scholar
5	Wang Q, Ding H, He Y, Li X, Cheng Y, Xu Q, Yang Y, Liao G, Meng X, Huang C and Li J: NLRC5 mediates cell proliferation, migration, and invasion by regulating the Wnt/β-catenin signalling pathway in clear cell renal cell carcinoma. Cancer Lett. 444:9–19. 2019.PubMed/NCBI View Article : Google Scholar
6	He YH, Li MF, Zhang XY, Meng XM, Huang C and Li J: NLRC5 promotes cell proliferation via regulating the AKT/VEGF-A signaling pathway in hepatocellular carcinoma. Toxicology. 359-360:47–57. 2016.PubMed/NCBI View Article : Google Scholar
7	Li Y, Zhang M and Zheng X: High expression of NLRC5 is associated with prognosis of gastric cancer. Open Med (Wars). 13:443–449. 2018.PubMed/NCBI View Article : Google Scholar
8	Oh SC, Sohn BH, Cheong JH, Kim SB, Lee JE, Park KC, Lee SH, Park JL, Park YY, Lee HS, et al: Clinical and genomic landscape of gastric cancer with a mesenchymal phenotype. Nat Commun. 9(1777)2018.PubMed/NCBI View Article : Google Scholar
9	Digklia A and Wagner AD: Advanced gastric cancer: Current treatment landscape and future perspectives. World J Gastroenterol. 22:2403–2414. 2016.PubMed/NCBI View Article : Google Scholar
10	Catalano C, da Silva Filho MI, Jiraskova K, Vymetalkova V, Levy M, Liska V, Vycital O, Naccarati A, Vodickova L, Hemminki K, et al: Short article: Influence of regulatory NLRC5 variants on colorectal cancer survival and 5-fluorouracil-based chemotherapy. Eur J Gastroenterol Hepatol. 30:838–842. 2018.PubMed/NCBI View Article : Google Scholar
11	Naidoo K, Clay V, Hoyland JA, Swindell R, Linton K, Illidge T, Radford JA and Byers RJ: YY1 expression predicts favourable outcome in follicular lymphoma. J Clin Pathol. 64:125–129. 2011.PubMed/NCBI View Article : Google Scholar
12	Kim H, Bang S, Jee S, Park S, Kim Y, Park H, Jang K and Paik SS: Loss of YY1 expression predicts unfavorable prognosis in stage III colorectal cancer. Indian J Pathol Microbiol. 64 (Supplement):S78–S84. 2021.PubMed/NCBI View Article : Google Scholar
13	Xia W, Li Y, Wu Z, Wang Y, Xing N, Yang W and Wu S: Transcription factor YY1 mediates epithelial-mesenchymal transition through the TGFβ signaling pathway in bladder cancer. Med Oncol. 37(93)2020.PubMed/NCBI View Article : Google Scholar
14	Kang W, Tong JH, Chan AW, Zhao J, Dong Y, Wang S, Yang W, Sin FM, Ng SS, Yu J, et al: Yin Yang 1 contributes to gastric carcinogenesis and its nuclear expression correlates with shorter survival in patients with early stage gastric adenocarcinoma. J Transl Med. 12(80)2014.PubMed/NCBI View Article : Google Scholar
15	Wang J, Wu X, Dai W, Li J, Xiang L, Tang W, Lin J, Zhang W, Liu G, Yang Q, et al: The CCDC43-ADRM1 axis regulated by YY1, promotes proliferation and metastasis of gastric cancer. Cancer Lett. 482:90–101. 2020.PubMed/NCBI View Article : Google Scholar
16	Zhang L, Zou L and Sun P: Relationship between miR-378c and YY1 expression in patients with gastric cancer and the clinicopathological features. Cell Mol Biol Lett. 26(12)2021.PubMed/NCBI View Article : Google Scholar
17	Messeguer X, Escudero R, Farre D, Nunez O, Martinez J and Alba MM: PROMO: Detection of known transcription regulatory elements using species-tailored searches. Bioinformatics. 18:333–334. 2002.PubMed/NCBI View Article : Google Scholar
18	Fornes O, Castro-Mondragon JA, Khan A, van der Lee R, Zhang X, Richmond PA, Modi BP, Correard S, Gheorghe M, Baranašić D, et al: JASPAR 2020: Update of the open-access database of transcription factor binding profiles. Nucleic Acids Res. 48:D87–D92. 2020.PubMed/NCBI View Article : Google Scholar
19	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.PubMed/NCBI View Article : Google Scholar
20	El-Rifai W and Powell SM: Molecular biology of gastric cancer. Semin Radiat Oncol. 12:128–140. 2002.PubMed/NCBI View Article : Google Scholar
21	Frycz BA, Murawa D, Borejsza-Wysocki M, Wichtowski M, Spychala A, Marciniak R, Murawa P, Drews M and Jagodziński PP: mRNA expression of steroidogenic enzymes, steroid hormone receptors and their coregulators in gastric cancer. Oncol Lett. 13:3369–3378. 2017.PubMed/NCBI View Article : Google Scholar
22	Yang T, Wang R, Zhang J, Bao C, Zhang J, Li R, Chen X, Wu S, Wen J, Wei S, et al: Mechanism of berberine in treating Helicobacter pylori induced chronic atrophic gastritis through IRF8-IFN-ү signaling axis suppressing. Life Sci. 248(117456)2020.PubMed/NCBI View Article : Google Scholar
23	Yang QY, Chen T, Chen YB and Lan DL: Molecular characterization and expression analysis of the NLR family CARD containing five transcripts in the pig. Pol J Vet Sci. 19:753–761. 2016.PubMed/NCBI View Article : Google Scholar
24	Zong Z, Song Y, Xue Y, Ruan X, Liu X, Yang C, Zheng J, Cao S, Li Z and Liu Y: Knockdown of LncRNA SCAMP1 suppressed malignant biological behaviours of glioma cells via modulating miR-499a-5p/LMX1A/NLRC5 pathway. J Cell Mol Med. 23:5048–5062. 2019.PubMed/NCBI View Article : Google Scholar
25	Fan Y, Dong Z, Shi Y, Sun S, Wei B and Zhan L: NLRC5 promotes cell migration and invasion by activating the PI3K/AKT signaling pathway in endometrial cancer. J Int Med Res. 48(300060520925352)2020.PubMed/NCBI View Article : Google Scholar
26	Li X, Guo F, Liu Y, Chen HJ, Wen F, Zou B, Li D, Qin Q, Liu X, Shen Y and Wang Y: NLRC5 expression in tumors and its role as a negative prognostic indicator in stage III non-small-cell lung cancer patients. Oncol Lett. 10:1533–1540. 2015.PubMed/NCBI View Article : Google Scholar
27	Ito S, Sano T, Mizusawa J, Takahari D, Katayama H, Katai H, Kawashima Y, Kinoshita T, Terashima M, Nashimoto A, et al: A phase II study of preoperative chemotherapy with docetaxel, cisplatin, and S-1 followed by gastrectomy with D2 plus para-aortic lymph node dissection for gastric cancer with extensive lymph node metastasis: JCOG1002. Gastric Cancer. 20:322–331. 2017.PubMed/NCBI View Article : Google Scholar
28	Guo XM, Liu XP, Chang GB, Xu L, Bi YL, Wang HZ, Zhang Y, Zhu PF, Wu Y and Chen GH: Characterization of the NLRC5 promoter in chicken: SNPs, regulatory elements and CpG islands. Anim Genet. 47:579–587. 2016.PubMed/NCBI View Article : Google Scholar